| 1 |
Kovacs JA, Gill VJ, Meshnick S, et al. New insights into transmission，diagnosis, and drug treatment of pneumocystis carinii pneumonia[J]. JAMA, 2001, 286(19): 2450-2460.
|
| 2 |
Kovacs JA, Masur H. Evolving health effects of pneumocystis: one hundred years of progress in diagnosis and treatment[J]. JAMA, 2009, 301(24): 2578-2585.
|
| 3 |
Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows pneumocystis carinii to be a member of the fungi[J]. Nature, 1988, 334(6182): 519-522.
|
| 4 |
Cushion MT, Stringer JR. Has the name really been changed? It has for most researchers[J]. Clin Infect Dis, 2005, 41(12): 1756-1758.
|
| 5 |
万 秋，唐莉歆. 获得性免疫缺陷综合征合并慢性阻塞性肺疾病的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(1): 129-131.
|
| 6 |
刘 青，宋春丽，周义文，等. 1例卡氏肺孢子菌感染患者的临床诊治分析及其对六胺银染色法检测的影响[J]. 抗感染药学，2019, 16(8): 1356-1359.
|
| 7 |
Ghembaza A, Vautier M, Cacoub P, et al. Risk factors and prevention of pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases[J]. Chest, 2020, 158(6): 2323-2332.
|
| 8 |
Shibata S, Kikuchi T. Pneumocystis pneumonia in HIV-1-infected patients[J]. Respir Investig, 2019, 57(3): 213-219.
|
| 9 |
Santosh D, Goel A, Birchall IW, et al. Evaluation of biliary ductal anatomy in potential living liver donors: comparison between MRCP and Gd-EOB-DTPA-enhanced MRI[J]. Abdom Radiol (NY), 2017, 42(10): 2428-2435.
|
| 10 |
许汝娟，武彦芳，任冬弓. CT增强扫描与MRCP在肝内胆管癌诊断中的应用对比研究[J]. 中国CT和MRI杂志，2016, 14(9): 80-82.
|
| 11 |
李 辉，陈富星，李铁丰. MRI诊断恶性胆道梗阻的临床应用分析[J]. 医学影像学杂志，2016, 26(1): 158-160.
|
| 12 |
姚 琼，管红梅，李小会，等. MRI及3D-MRCP在婴幼儿胆道闭锁诊断中的影像研究[J]. 临床放射学杂志，2016, 35(12): 1876-1879.
|
| 13 |
吴晓军. CT与MRCP诊断胆道系统结石的影像学对比分析及应用价值评价[J]. 中国CT和MRI杂志，2016, 14(12): 80-82.
|
| 14 |
Teer E, Essop MF. HIV and cardiovascular disease: Role of immunometabolic perturbations[J]. Physiology (Bethesda), 2018, 33(1): 74-82.
|
| 15 |
Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system[J]. Mucosal Immunol, 2008, 1(1): 23-30.
|
| 16 |
Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection[J]. Nat Med, 2006, 12(12): 1365-1371.
|
| 17 |
Palmer CS, Cherry CL, Sada-Ovalle I, et al. Glucose metabolism in T cells and monocytes: New perspectives in HIV pathogenesis[J]. EBio Med, 2016, 6: 31-41.
|
| 18 |
Anzinger JJ, Butterfield TR, Angelovich TA, et al. Monocytes as regulators of inflammation and HIV-related comorbidities during cART[J]. J Immunol Res, 2014, 2014: 569819.
|
| 19 |
Palmer CS, Anzinger JJ, Zhou J, et al. Glucose transporter 1-expressing proinflammatory monocytes are elevated in combination antiretroviral therapy-treated and untreated HIV+ subjects[J]. J Immunol, 2014, 193(11): 5595-5603.
|
| 20 |
Palmer CS, Crowe SM. How does monocyte metabolism impact inflammation and aging during chronic HIV infection？[J]. AIDS Res Hum Retroviruses, 2014, 30(4): 335-336.
|
| 21 |
Hansson GK. Immune mechanisms in atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2001, 21(12): 1876-1890.
|
| 22 |
Triant VA. HIV infection and coronary heart disease: an intersection of epidemics[J]. J Infect Dis, 2012, 205(Suppl 3): S355-S361.
|
| 23 |
Cerrato E, Calcagno A, D′Ascenzo F, et al. Cardiovascular disease in HIV patients: from bench to bedside and backwards[J]. Open Heart, 2015, 2(1): e174.
|
| 24 |
Dube MP, Lipshultz SE, Fichtenbaum CJ, et al. Effects of HIV infection and antiretroviral therapy on the heart and vasculature[J]. Circul, 2008, 118(2): e36-e40.
|
| 25 |
Reyskens KM, Essop MF. The maladaptive effects of HIV protease inhibitors (lopinavir/ritonavir) on the rat heart[J]. Int J Cardiol, 2013, 168(3): 3047-3049.
|
| 26 |
Le T, Kinh NV, Cuc N, et al. A Trial of Itraconazole or amphotericin B for HIV-associated talaromycosis[J]. N Engl J Med, 2017, 376(24): 2329-2340.
|
| 27 |
揣征然，张云辉，赵雅琳，等. 全球及中国AIDS最新疫情概况[J]. 传染病信息，2020, 33(6): 501-503.
|
| 28 |
连玉婷，赵 燕. HIV母婴阻断及HIV感染婴幼儿抗病毒药物致线粒体损伤研究进展[J]. 中国艾滋病性病，2021, 27(2): 213-215.
|
| 29 |
刘旭辉，云 鹰. HIV/AIDS相关性肾损伤的病因及早期监测研究进展[J]. 医学综述，2009, 15(8): 1239-1241.
|
| 30 |
Schmidt JJ, Lueck C, Ziesing S, et al. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years[J]. Crit Care, 2018, 22(1): 307.
|